Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of OMS302 during cataract surgery
2012-000867-25Phase 3Completed
- Sponsor
- Omeros Corporation
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cataract comparing OMS302 with Placebo (2 arms). Primary endpoints: Change in pupil diameter over time and Early postoperative pain. Started May 2012; status: completed.
02
Drugs
phenylephrine + ketorolac
03
Conditions
cataract
Beyond the preview
Go deeper on 2012-000867-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000867-25.